Protagonist Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Protagonist Therapeutics Inc PTGX.OQ reported a quarterly adjusted loss of 55 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -50 cents. The mean expectation of twelve analysts for the quarter was for a loss of 58 cents per share. Wall Street expected results to range from -76 cents to -24 cents per share.

• Revenue rose 33.1% to $5.55 million from a year ago; analysts expected $6.81 million.

• Protagonist Therapeutics Inc's reported EPS for the quarter was a loss of 55 cents​.

• The company reported a quarterly loss of $34.77 million.

• Protagonist Therapeutics Inc shares had fallen by 2.5% this quarter and gained 39.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.9% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Protagonist Therapeutics Inc is $70.00, about 23% above its last closing price of $53.90

This summary was machine generated from LSEG data August 6 at 09:12 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)